{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:38:14Z","timestamp":1787841494505,"version":"build-2784847793"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T00:00:00Z","timestamp":1501027200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T00:00:00Z","timestamp":1501027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["T32 DK007674"],"award-info":[{"award-number":["T32 DK007674"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["T32 DK007446"],"award-info":[{"award-number":["T32 DK007446"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K23 AR070275"],"award-info":[{"award-number":["K23 AR070275"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Research Foundation of Oregon","award":["MRF515"],"award-info":[{"award-number":["MRF515"]}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR000128"],"award-info":[{"award-number":["UL1TR000128"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P01 AG009975"],"award-info":[{"award-number":["P01 AG009975"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s00198-017-4162-5","type":"journal-article","created":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T23:35:55Z","timestamp":1501025755000},"page":"3205-3213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["24-hour profile of serum sclerostin and its association with bone biomarkers in men"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1554-0862","authenticated-orcid":false,"given":"C.","family":"Swanson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. A.","family":"Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Markwardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. W.","family":"Cain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Munch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. A.","family":"Czeisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. S.","family":"Orwoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. M.","family":"Buxton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,26]]},"reference":[{"issue":"1","key":"4162_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S8756-3282(02)00791-3","volume":"31","author":"P Qvist","year":"2002","unstructured":"Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C (2002) Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 31(1):57\u201361","journal-title":"Bone"},{"issue":"4","key":"4162_CR2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1530\/EJE-10-1108","volume":"164","author":"M Luchavova","year":"2011","unstructured":"Luchavova M, Zikan V, Michalska D, Raska I Jr, Kubena AA, Stepan JJ (2011) The effect of timing of teriparatide treatment on the circadian rhythm of bone turnover in postmenopausal osteoporosis. Eur J Endocrinol 164(4):643\u2013648. doi:\n                    10.1530\/EJE-10-1108","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"4162_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00198-007-0423-z","volume":"19","author":"A Dovio","year":"2008","unstructured":"Dovio A, Generali D, Tampellini M, Berruti A, Tedoldi S, Torta M, Bonardi S, Tucci M, Allevi G, Aguggini S, Bottini A, Dogliotti L, Angeli A (2008) Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis. Osteoporos Int 19(1):113\u2013117. doi:\n                    10.1007\/s00198-007-0423-z","journal-title":"Osteoporos Int"},{"key":"4162_CR4","unstructured":"Szulc P, Bauer DC (2013) Biochemical markers of bone turnover in osteoporosis. In: Marcus R, Feldman D, Dempster DW, Luckey M, Cauley JA (eds) Osteoporosis: fourth edition. 4th edn. Academic Press, Elsevier, Waltham, pp 1573\u20131610"},{"issue":"5","key":"4162_CR5","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1210\/er.2012-1026","volume":"34","author":"SL Dallas","year":"2013","unstructured":"Dallas SL, Prideaux M, Bonewald LF (2013) The osteocyte: an endocrine cell \u2026 and more. Endocr Rev 34(5):658\u2013690. doi:\n                    10.1210\/er.2012-1026","journal-title":"Endocr Rev"},{"issue":"9","key":"4162_CR6","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1210\/jc.2012-1811","volume":"97","author":"ER Smith","year":"2012","unstructured":"Smith ER, Cai MM, McMahon LP, Holt SG (2012) Biological variability of plasma intact and C-terminal FGF23 measurements. J Clin Endocrinol Metab 97(9):3357\u20133365. doi:\n                    10.1210\/jc.2012-1811","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"4162_CR7","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1074\/jbc.M113.500850","volume":"289","author":"M Kawai","year":"2014","unstructured":"Kawai M, Kinoshita S, Shimba S, Ozono K, Michigami T (2014) Sympathetic activation induces skeletal Fgf23 expression in a circadian rhythm-dependent manner. J Biol Chem 289(3):1457\u20131466. doi:\n                    10.1074\/jbc.M113.500850","journal-title":"J Biol Chem"},{"key":"4162_CR8","doi-asserted-by":"crossref","unstructured":"Swanson CM, Shea SA, Wolfe P, Cain SW, Munch M, Vujovic N, Czeisler CA, Buxton OM, Orwoll ES (accepted 2017) Bone turnover markers after sleep restriction and circadian disruption: a mechanism for sleep-related bone loss in humans. J Clin Endocrinol Metab","DOI":"10.1210\/jc.2017-01147"},{"issue":"129","key":"4162_CR9","doi-asserted-by":"publisher","first-page":"129ra143","DOI":"10.1126\/scitranslmed.3003200","volume":"4","author":"OM Buxton","year":"2012","unstructured":"Buxton OM, Cain SW, O\u2019Connor SP, Porter JH, Duffy JF, Wang W, Czeisler CA, Shea SA (2012) Adverse metabolic consequences in humans of prolonged sleep restriction combined with circadian disruption. Sci Transl Med 4(129):129ra143. doi:\n                    10.1126\/scitranslmed.3003200","journal-title":"Sci Transl Med"},{"key":"4162_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1742-4682-11-16","volume":"11","author":"G Cornelissen","year":"2014","unstructured":"Cornelissen G (2014) Cosinor-based rhythmometry. Theor Biol Med Model 11:16. doi:\n                    10.1186\/1742-4682-11-16","journal-title":"Theor Biol Med Model"},{"issue":"4, series B","key":"4162_CR11","first-page":"329","volume":"38","author":"JS Rao","year":"1976","unstructured":"Rao JS (1976) Some tests based on arc-lengths for the circle. Sankhya 38(4, series B):329\u2013338","journal-title":"Sankhya"},{"key":"4162_CR12","unstructured":"R Core Team (2014) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna. \n                    http:\/\/www.R-project.org\/"},{"key":"4162_CR13","unstructured":"Santosh HS, Ahluwalia R, Hamilton A, Barraclough DL, Fraser WD, Vora JP (2013) Circadian rhythm of circulating sclerostin in healthy young men. Presented at 15th European Congress of Endocrinology. Endocrine Abstracts, Copenhagen vol 32. p P72"},{"key":"4162_CR14","doi-asserted-by":"publisher","unstructured":"Redmond J, Fulford AJ, Jarjou L, Zhou B, Prentice A (2016) Schoenmakers I. Diurnal Rhythms of Bone Turnover Markers in Three Ethnic Groups. J Clin Endocrinol Metab 101(8):3222\u20133230. doi:\n                    10.1210\/jc.2016-1183","DOI":"10.1210\/jc.2016-1183"},{"key":"4162_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bone.2013.12.026","volume":"61","author":"Y Fujihara","year":"2014","unstructured":"Fujihara Y, Kondo H, Noguchi T, Togari A (2014) Glucocorticoids mediate circadian timing in peripheral osteoclasts resulting in the circadian expression rhythm of osteoclast-related genes. Bone 61:1\u20139. doi:\n                    10.1016\/j.bone.2013.12.026","journal-title":"Bone"},{"issue":"5","key":"4162_CR16","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.cell.2005.06.028","volume":"122","author":"L Fu","year":"2005","unstructured":"Fu L, Patel MS, Bradley A, Wagner EF, Karsenty G (2005) The molecular clock mediates leptin-regulated bone formation. Cell 122(5):803\u2013815. doi:\n                    10.1016\/j.cell.2005.06.028","journal-title":"Cell"},{"key":"4162_CR17","doi-asserted-by":"publisher","unstructured":"Yuan G, Hua B, Yang Y, Xu L, Cai T, Sun N, Yan Z, Lu C, Qian R (2016) The circadian gene clock regulates bone formation via PDIA3. J Bone Miner Res. doi:\n                    10.1002\/jbmr.3046","DOI":"10.1002\/jbmr.3046"},{"issue":"7","key":"4162_CR18","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1002\/jbmr.2803","volume":"31","author":"C Xu","year":"2016","unstructured":"Xu C, Ochi H, Fukuda T, Sato S, Sunamura S, Takarada T, Hinoi E, Okawa A, Takeda S (2016) Circadian clock regulates bone resorption in mice. J Bone Miner Res 31(7):1344\u20131355. doi:\n                    10.1002\/jbmr.2803","journal-title":"J Bone Miner Res"},{"key":"4162_CR19","doi-asserted-by":"publisher","unstructured":"Takarada T, Xu C, Ochi H, Nakazato R, Yamada D, Nakamura S, Kodama A, Shimba S, Mieda M, Fukasawa K, Ozaki K, Iezaki T, Fujikawa K, Yoneda Y, Numano R, Hida A, Tei H, Takeda S, Hinoi E (2016) Bone resorption is regulated by circadian clock in osteoblasts. J Bone Miner Res. doi:\n                    10.1002\/jbmr.3053","DOI":"10.1002\/jbmr.3053"},{"issue":"7","key":"4162_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011527","volume":"5","author":"E Maronde","year":"2010","unstructured":"Maronde E, Schilling AF, Seitz S, Schinke T, Schmutz I, van der Horst G, Amling M, Albrecht U (2010) The clock genes period 2 and cryptochrome 2 differentially balance bone formation. PLoS One 5(7):e11527. doi:\n                    10.1371\/journal.pone.0011527","journal-title":"PLoS One"},{"issue":"9","key":"4162_CR21","doi-asserted-by":"publisher","first-page":"3873","DOI":"10.1210\/jc.2013-2113","volume":"98","author":"C Durosier","year":"2013","unstructured":"Durosier C, van Lierop A, Ferrari S, Chevalley T, Papapoulos S, Rizzoli R (2013) Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women. J Clin Endocrinol Metab 98(9):3873\u20133883. doi:\n                    10.1210\/jc.2013-2113","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"4162_CR22","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00198-012-1978-x","volume":"24","author":"P Garnero","year":"2013","unstructured":"Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat RD (2013) Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int 24(2):489\u2013494. doi:\n                    10.1007\/s00198-012-1978-x","journal-title":"Osteoporos Int"},{"issue":"5","key":"4162_CR23","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1210\/jc.2010-0067","volume":"95","author":"A Gaudio","year":"2010","unstructured":"Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, Pulvirenti I, Hawa G, Tringali G, Fiore CE (2010) Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 95(5):2248\u20132253. doi:\n                    10.1210\/jc.2010-0067","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"4162_CR24","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1002\/jbmr.474","volume":"26","author":"AH van Lierop","year":"2011","unstructured":"van Lierop AH, Hamdy NA, Hamersma H, van Bezooijen RL, Power J, Loveridge N, Papapoulos SE (2011) Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res 26(12):2804\u20132811. doi:\n                    10.1002\/jbmr.474","journal-title":"J Bone Miner Res"},{"issue":"4","key":"4162_CR25","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/jbmr.1794","volume":"28","author":"AH van Lierop","year":"2013","unstructured":"van Lierop AH, Hamdy NA, van Egmond ME, Bakker E, Dikkers FG, Papapoulos SE (2013) Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers. J Bone Miner Res 28(4):848\u2013854. doi:\n                    10.1002\/jbmr.1794","journal-title":"J Bone Miner Res"},{"issue":"8","key":"4162_CR26","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/jbmr.376","volume":"26","author":"M Frost","year":"2011","unstructured":"Frost M, Andersen T, Gossiel F, Hansen S, Bollerslev J, van Hul W, Eastell R, Kassem M, Brixen K (2011) Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high-bone-mass phenotype due to a mutation in Lrp5. J Bone Miner Res 26(8):1721\u20131728. doi:\n                    10.1002\/jbmr.376","journal-title":"J Bone Miner Res"},{"issue":"1","key":"4162_CR27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.bone.2012.04.016","volume":"51","author":"MP Yavropoulou","year":"2012","unstructured":"Yavropoulou MP, van Lierop AH, Hamdy NA, Rizzoli R, Papapoulos SE (2012) Serum sclerostin levels in Paget\u2019s disease and prostate cancer with bone metastases with a wide range of bone turnover. Bone 51(1):153\u2013157. doi:\n                    10.1016\/j.bone.2012.04.016","journal-title":"Bone"},{"key":"4162_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bone.2013.10.019","volume":"59","author":"MM Roforth","year":"2014","unstructured":"Roforth MM, Fujita K, McGregor UI, Kirmani S, McCready LK, Peterson JM, Drake MT, Monroe DG, Khosla S (2014) Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans. Bone 59:1\u20136. doi:\n                    10.1016\/j.bone.2013.10.019","journal-title":"Bone"},{"key":"4162_CR29","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/bonekey.2013.95","volume":"2","author":"BL Clarke","year":"2013","unstructured":"Clarke BL, Drake MT (2013) Clinical utility of serum sclerostin measurements. Bonekey Rep 2:361","journal-title":"Bonekey Rep"},{"issue":"6","key":"4162_CR30","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1007\/s00223-015-0105-3","volume":"98","author":"I Piec","year":"2016","unstructured":"Piec I, Washbourne C, Tang J, Fisher E, Greeves J, Jackson S, Fraser WD (2016) How accurate is your sclerostin measurement? Comparison between three commercially available sclerostin ELISA kits. Calcif Tissue Int 98(6):546\u2013555. doi:\n                    10.1007\/s00223-015-0105-3","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"4162_CR31","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1210\/jcem.87.7.8480","volume":"87","author":"JS Finkelstein","year":"2002","unstructured":"Finkelstein JS, Sowers M, Greendale GA, Lee ML, Neer RM, Cauley JA, Ettinger B (2002) Ethnic variation in bone turnover in pre- and early perimenopausal women: effects of anthropometric and lifestyle factors. J Clin Endocrinol Metab 87(7):3051\u20133056. doi:\n                    10.1210\/jcem.87.7.8480","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"4162_CR32","doi-asserted-by":"publisher","first-page":"4736","DOI":"10.1210\/jc.2013-2106","volume":"98","author":"AG Costa","year":"2013","unstructured":"Costa AG, Walker MD, Zhang CA, Cremers S, Dworakowski E, McMahon DJ, Liu G, Bilezikian JP (2013) Circulating sclerostin levels and markers of bone turnover in Chinese-American and white women. J Clin Endocrinol Metab 98(12):4736\u20134743. doi:\n                    10.1210\/jc.2013-2106","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"4162_CR33","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1210\/jc.2011-2152","volume":"97","author":"K Amrein","year":"2012","unstructured":"Amrein K, Amrein S, Drexler C, Dimai HP, Dobnig H, Pfeifer K, Tomaschitz A, Pieber TR, Fahrleitner-Pammer A (2012) Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab 97(1):148\u2013154. doi:\n                    10.1210\/jc.2011-2152","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"4162_CR34","doi-asserted-by":"publisher","first-page":"4662","DOI":"10.1210\/jc.2015-2957","volume":"100","author":"P Chavassieux","year":"2015","unstructured":"Chavassieux P, Portero-Muzy N, Roux JP, Garnero P, Chapurlat R (2015) Are biochemical markers of bone turnover representative of bone histomorphometry in 370 postmenopausal women? J Clin Endocrinol Metab 100(12):4662\u20134668. doi:\n                    10.1210\/jc.2015-2957","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-017-4162-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-017-4162-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-017-4162-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T07:41:05Z","timestamp":1589442065000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-017-4162-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,26]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["4162"],"URL":"https:\/\/doi.org\/10.1007\/s00198-017-4162-5","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,26]]},"assertion":[{"value":"2 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"In the interest of full disclosure, we report the following; however, we do not believe any of these pertain to the current work.C.M.S. received support from NIH grant T32 DK007674, NIH grant T32 DK007446, K23 AR070275, and the Medical Research Foundation of Oregon Early Clinical Investigator Grant MRF515.S.A.S. received support from NASA grant NNX1OAR1OG, CDC grant U19 OH010154, and NIH grant R01 HL125893.P.W., S.W.C., and M.M. have no disclosures.S.M. received support from the Oregon Clinical and Translational Research Institute (OCTRI), grant number UL1TR000128 from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH).C.A.C. is consultant to , Inc., A2Z Development Center, Bose, Boston Celtics, Boston Red Sox, Cleveland Browns, Columbia River Bar Pilots, Institute of Digital Media and Child Development, Jazz Pharma, Merck, NBA Coaches Association, Purdue Pharma, Quest Diagnostics, Samsung, Teva, and Vanda Pharma. C.A.C. holds equity in Vanda Pharma; receives research\/education support from Cephalon, Mary Ann & Stanley Snider via Combined Jewish Philanthropies, NFL Charities, Jazz Pharma, Optum, ResMed, San Francisco Bar Pilots, Schneider, Simmons, Sysco, Philips, and Vanda; is an expert witness in legal cases, including those involving Bombardier, Continental Airlines, Fedex, Greyhound, Purdue Pharma, and UPS; serves as the incumbent of a professorship endowed by Cephalon; and receives royalties from McGraw Hill, Houghton Miflin Harcourt, and Philips Respironics for the Actiwatch-2 and Actiwatch Spectrum devices. C.A.C.\u2019s interests were reviewed and are managed by Brigham and Women\u2019s Hospital and Partners HealthCare in accordance with their conflict of interest policies.O.M.B. previously served as consultant to Takeda Pharmaceuticals North America (speaker\u2019s bureau), Dinsmore LLC (expert witness testimony), Matsutani America (scientific advisory board), and Chevron (speaking fees). Outside of the submitted work, investigator-initiated research grant support from Sepracor (now Sunovion) and Cephalon (now Teva). This work was supported by grants from the National Institute on Aging (NIA) (P01 AG009975) and was conducted in the Brigham and Women\u2019s Hospital General Clinical Research Center supported by the National Center for Research Resources (NCRR) (M01 RR02635), the CCI of the Harvard Clinical and Translational Science Center (1 UL1 RR025758-01), and with support from the Joslin Diabetes and Endocrinology Research Center Service (5P30 DK 36836) Specialized Assay Core. O.M.B. was supported in part by the NHLBI (R01HL107240).E.S.O. consults for and has received research support from Amgen, Lilly, and Merck.E.S.O. for The Osteoporotic Fractures in Men (MrOS) Study, and the National Institutes of Health via the following institutes: the National Institute on Aging (NIA), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Center for Advancing Translational Sciences (NCATS), and NIH Roadmap for Medical Research, under the following grant numbers: U01AG027810, U01 AG042124, U01 AG042139, U01 AG042140,U01 AG042143, U01 AG042145, U01 AG042168, U01AR066160, and UL1 TR000128.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial disclosures\/conflict of interest"}}]}}